Print this page    •   Back to Web version of article

U.S. News
FDA Fast Tracks AbbVie Hepatitis C Drug

May 8, 2013

According to AbbVie, the Food and Drug Administration (FDA) has given its new hepatitis C drug regimen a breakthrough therapy designation, which will speed up its potential approval in the United States. The FDA's designation stems from clinical trial results, which have shown a high response rate to the combination therapy in which patients receive 12–24 weeks of treatment with nearly one year of post-treatment follow-up.

Back to other news for May 2013

Excerpted from:
Chicago Tribune
05.06.2013; Samantha Bomkamp

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.